For the past year or so, Acidophil has been developing Chalante, based in Cambridge UK. Over this time, Chalante has been supported by a combination of seed investment from Acidophil and Innovate UK grants. We are currently seeking additional investors to join Acidophil in a Series A round, to accelerate Chalante’s programs and reach key value inflection points.
Chalante aims to serve as an external source of innovation for the established animal medicines industry. We are developing novel bioactive molecules as well as methods for their production, to serve as parasiticides or feed conversion enhancers for food and/or companion animals. Our lead programs are designed to enable production of high quality protein without hormones or antibiotics, overcome the threat of resistance to older drugs and respond to greater spending on pet animal care.